Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moellering, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moellering, R. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, Topic A, 25-30
© 1999 The British Society for Antimicrobial Chemotherapy

Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections

Robert C. Moellering*

Department of Medicine, Beth Israël Deaconess Medical Center, 110 Francis Street, Suite 6A, Boston, MA 02215, USA

Vancomycin-resistant Enterococcus faecium (VREF) is an opportunistic pathogen, which causes infections among severely ill, hospitalized patients, in whom it is likely to increase the risk of progressive local or systemic disease and to worsen the prognosis. Because these organisms are often highly resistant to penicillin, ampicillin and many other antimicrobials including the glycopeptides, there are few proven therapeutic alternatives for the treatment of infection caused by VREF. Quinupristin/dalfopristin is highly active against VREF in vitro. A prolonged post-antibiotic effect, good polymorphonuclear leucocyte/macrophage penetration and slow release, and active metabolites allow this agent to be used with an 8 or 12 h dosing interval. The combined results from a Phase III non-comparative study and an emergency-use study of quinupristin/dalfopristin for the treatment of VREF infection produced a clinical response rate (cure or improvement) in 142 (73.6%) of 193 clinically evaluable patients. The baseline pathogen was eradicated or presumed eradicated from 110 of 156 (70.5%) bacteriologically evaluable patients. Fifty-two per cent of the severely ill patients in these two studies died, but no death was attributed to quinupristin/dalfopristin therapy. The most common adverse event was arthralgia (9.1%). Quinupristin/dalfopristin has demonstrated efficacy for the treatment of serious VREF infections, including those that have failed conventional therapy.

* Tel: +1-617-632-85-86; Fax: +1-617-632-74-39


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
P. Butaye, L. A. Devriese, and F. Haesebrouck
Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria
Clin. Microbiol. Rev., April 1, 2003; 16(2): 175 - 188.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. C. Moellering Jr.
Linezolid: The First Oxazolidinone Antimicrobial
Ann Intern Med, January 21, 2003; 138(2): 135 - 142.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. J. Rehm, D. R. Graham, L. Srinath, P. Prokocimer, M.-P. Richard, and G. H. Talbot
Successful administration of quinupristin/dalfopristin in the outpatient setting
J. Antimicrob. Chemother., May 1, 2001; 47(5): 639 - 645.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.